Description

For decades we've been told the same story: antibodies are extracellular drugs only. ~90% of the proteome – the real treasure trove of "undruggable" targets – stays forever out of reach behind the plasma membrane. Not anymore. A single, precisely placed non-canonical amino acid can turn a tiny domain antibody (nanobody, monobody, DARPin – you name it) into a cell-penetrating missile that actually works inside living cells.

The group took a fibronectin type III monobody, supercharged it to +18 net charge, genetically encoded a β-lactam-lysine (BeLaK) at the N-terminus, watched it spontaneously form an intramolecular covalent strap with a nearby lysine. The result: spontaneous uptake at only 40 nM, clean endosomal escape, and sub-micromolar inhibition of ERK1/2 phosphorylation in esophageal cancer cells.

Citation: Rabb et al., 2025

Most biologics work outside cells because proteins cannot cross the plasma membrane. Roughly 90% of the human proteome sits inside cells, beyond the reach of conventional antibodies and nanobodies. Non-canonical amino acids can change that.

In 2025, researchers genetically encoded beta-lactam-lysine (BeLaK) at the N-terminus of a fibronectin type III monobody. BeLaK spontaneously formed an intramolecular covalent bond with a nearby lysine, creating a structural "strap" that promoted cellular uptake. The modified monobody entered cells at just 40 nM concentration, escaped endosomes cleanly, and inhibited ERK1/2 phosphorylation at sub-micromolar levels in esophageal cancer cells (Rabb et al., 2025).

This single ncAA modification converts an extracellular binder into a cell-penetrating therapeutic. Similar scaffolds such as nanobodies and DARPins could in principle use the same strategy. For drug developers, it opens the intracellular proteome to biologic intervention without requiring cell-penetrating peptide fusions or lipid nanoparticle delivery.

Source publication